[Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay].

Camejo-Martínez N, Strazzarino-Peluffo N, Amarillo-Hernández C D, Castillo-Leska C, Krygier-Waltier G

DOI: 10.5281/zenodo.18715279
Published: 2026 May 6
Container: Revista medica del Instituto Mexicano del Seguro Social
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.5281/zenodo.18715279,
  title = {[Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay].},
  author = {Camejo-Martínez N and Strazzarino-Peluffo N and Amarillo-Hernández C D and Castillo-Leska C and Krygier-Waltier G},
  year = {2026},
  journal = {Revista medica del Instituto Mexicano del Seguro Social},
  doi = {10.5281/zenodo.18715279},
  url = {https://doi.org/10.5281/zenodo.18715279}
}

RIS

TY  - JOUR
TI  - [Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay].
AU  - Camejo-Martínez N
AU  - Strazzarino-Peluffo N
AU  - Amarillo-Hernández C D
AU  - Castillo-Leska C
AU  - Krygier-Waltier G
PY  - 2026
JO  - Revista medica del Instituto Mexicano del Seguro Social
DO  - 10.5281/zenodo.18715279
UR  - https://doi.org/10.5281/zenodo.18715279
ER  -

APA

N, C., N, S., D, A. C., C, C., & G, K. (2026). [Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay].. Revista medica del Instituto Mexicano del Seguro Social. https://doi.org/10.5281/zenodo.18715279

Source records

pubmed · retrieved 2026-09-26T18:45:52.287Z